Patents by Inventor Rohan V. Mendonca

Rohan V. Mendonca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11612606
    Abstract: 3-Carbonylamino-8-aminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylamino-8-aminoisoquinoline compounds.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: March 28, 2023
    Assignee: Genentech, Inc.
    Inventors: Jun Liang, Rohan V. Mendonca, Michael Siu, John Tellis, Weiru Wang, BinQing Wei, Bryan Chan, Edna F. Choo, Joy Drobnick, Lewis J. Gazzard, Timothy Heffron
  • Publication number: 20210332064
    Abstract: 3-Carbonylaminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylaminoisoquinoline compounds.
    Type: Application
    Filed: April 1, 2021
    Publication date: October 28, 2021
    Applicant: Genentech, Inc.
    Inventors: Jun Liang, Rohan V. Mendonca, Michael Siu, John Tellis, Weiru Wang, BinQing Wei, Bryan Chan, Edna F. Choo, Joy Drobnick, Lewis J. Gazzard, Timothy Heffron
  • Publication number: 20210277024
    Abstract: Naphthyridine compounds of formula (I). variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
    Type: Application
    Filed: January 22, 2021
    Publication date: September 9, 2021
    Applicant: Genentech, Inc.
    Inventors: Terry Kellar, Jun Liang, Sushant Malhotra, Rohan V. Mendonca, Michael Siu, Craig Stivala, John C. Tellis, BinQing Wei, Bryan K. Chan, Lewis J. Gazzard, Timothy Heffron, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
  • Publication number: 20210253580
    Abstract: Isoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
    Type: Application
    Filed: January 22, 2021
    Publication date: August 19, 2021
    Applicant: Genentech, Inc.
    Inventors: Jun Liang, Sushant Malhotra, Rohan V. Mendonca, Naomi Rajapaksa, Michael Siu, Craig Stivala, John C. Tellis, BinQing Wei, Bryan K. Chan, Joy Alison Drobnick, Lewis J. Gazzard, Timothy Heffron, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
  • Publication number: 20200108075
    Abstract: 3-Carbonylamino-8-aminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylamino-8-aminoisoquinoline compounds.
    Type: Application
    Filed: October 3, 2019
    Publication date: April 9, 2020
    Applicant: Genentech, Inc.
    Inventors: Jun LIANG, Rohan V. MENDONCA, Michael SIU, John TELLIS, Weiru WANG, BinQing WEI, Bryan CHAN, Edna F. CHOO, Joy DROBNICK, Lewis J. GAZZARD, Timothy HEFFRON
  • Publication number: 20030092634
    Abstract: The present invention relates to novel cysteine protease inhibitors; the pharmaceutically acceptable salts and N-oxides thereof; their uses as therapeutic agents and the methods of their making.
    Type: Application
    Filed: November 4, 2002
    Publication date: May 15, 2003
    Applicant: Axys Pharmaceuticals, Inc.
    Inventors: Ann M. Buysse, Rohan V. Mendonca, James T. Palmer, Zong-Qiang Tian, Shankar Venkatraman
  • Patent number: 6525036
    Abstract: The present invention relates to novel cysteine protease inhibitors of Formula I: the pharmaceutically acceptable salts and N-oxide derivatives thereof, their use as therapeutic agents and methods of making them.
    Type: Grant
    Filed: January 5, 2001
    Date of Patent: February 25, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Renata Marcella Oballa, Petpiboon Prasit, Joel Stephane Robichaud, Elise Isabel, Eduardo Setti, Dan-Xiong Wang, Rohan V. Mendonca, Shankar Venkatraman
  • Patent number: 6506733
    Abstract: Compounds of the formula: are provided, and are useful as cysteine protease inhibitors, particularly in the treatment of diseases such as osteoporosis or autoimmune disorders in which cathepsins K or S contribute to the pathology or symptomatolgy of the disease.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: January 14, 2003
    Assignee: Axys Pharmaceuticals, Inc.
    Inventors: Ann M. Buysse, Rohan V. Mendonca, James T. Palmer, Zong-Qiang Tian, Shankar Venkatraman
  • Publication number: 20020052378
    Abstract: The present invention relates to novel cysteine protease inhibitors of Formula I: 1
    Type: Application
    Filed: January 5, 2001
    Publication date: May 2, 2002
    Inventors: Renata Marcella Oballa, Petpiboon Prasit, Joel Stephane Robichaud, Elise Isabel, Eduardo Setti, Dan-Xiong Wang, Rohan V. Mendonca, Shankar Venkatraman